Az adalimumab biológiai terápia hatékonysága és biztonságossága

Translated title of the contribution: The effectivity and safety of the biological therapy with adalimumab

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The adalimumab is a human, recombinant antibody, which is able to give an effective therapy modality in patients with rheumatoid arthritis, polyarticular juvenil idiopathic arthritis, psoriasis, arthritis psoriatica, spondylitis ankylopoetica, as well as with Crohn-disease. The adalimumab has got a high affinity binding to tumor necrosis factor (TNF) -alfa, this way it inhibits the interactions with TNF and its receptors (soluble and membrane associated). It could be well tolerated and safe, it improves the the quality of life in patients. The possible side effects can be decreased by the careful observation and usual control of patients. The authors discuss in details the publications connected with adalimumab in the above mentioned diseases.

Original languageHungarian
Pages (from-to)1215-1222
Number of pages8
JournalOrvosi Hetilap
Volume150
Issue number26
DOIs
Publication statusPublished - Jun 1 2009

Fingerprint

Biological Therapy
Safety
Arthritis
Spondylitis
Tumor Necrosis Factor Receptors
Psoriasis
Crohn Disease
Publications
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Quality of Life
Observation
Membranes
Antibodies
Adalimumab
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az adalimumab biológiai terápia hatékonysága és biztonságossága. / Fehér, J.; Lengyel, G.

In: Orvosi Hetilap, Vol. 150, No. 26, 01.06.2009, p. 1215-1222.

Research output: Contribution to journalArticle

@article{fedc0e3a4e5248e5a1176f26401b189e,
title = "Az adalimumab biol{\'o}giai ter{\'a}pia hat{\'e}konys{\'a}ga {\'e}s biztons{\'a}goss{\'a}ga",
abstract = "The adalimumab is a human, recombinant antibody, which is able to give an effective therapy modality in patients with rheumatoid arthritis, polyarticular juvenil idiopathic arthritis, psoriasis, arthritis psoriatica, spondylitis ankylopoetica, as well as with Crohn-disease. The adalimumab has got a high affinity binding to tumor necrosis factor (TNF) -alfa, this way it inhibits the interactions with TNF and its receptors (soluble and membrane associated). It could be well tolerated and safe, it improves the the quality of life in patients. The possible side effects can be decreased by the careful observation and usual control of patients. The authors discuss in details the publications connected with adalimumab in the above mentioned diseases.",
keywords = "Adalimumab, Crohn disease, Psoriasis, Rheumatoid arthritis, Spondylitis ankylopoetica, Tumor necrosis factor inhibition",
author = "J. Feh{\'e}r and G. Lengyel",
year = "2009",
month = "6",
day = "1",
doi = "10.1556/OH.2009.28681",
language = "Hungarian",
volume = "150",
pages = "1215--1222",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "26",

}

TY - JOUR

T1 - Az adalimumab biológiai terápia hatékonysága és biztonságossága

AU - Fehér, J.

AU - Lengyel, G.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The adalimumab is a human, recombinant antibody, which is able to give an effective therapy modality in patients with rheumatoid arthritis, polyarticular juvenil idiopathic arthritis, psoriasis, arthritis psoriatica, spondylitis ankylopoetica, as well as with Crohn-disease. The adalimumab has got a high affinity binding to tumor necrosis factor (TNF) -alfa, this way it inhibits the interactions with TNF and its receptors (soluble and membrane associated). It could be well tolerated and safe, it improves the the quality of life in patients. The possible side effects can be decreased by the careful observation and usual control of patients. The authors discuss in details the publications connected with adalimumab in the above mentioned diseases.

AB - The adalimumab is a human, recombinant antibody, which is able to give an effective therapy modality in patients with rheumatoid arthritis, polyarticular juvenil idiopathic arthritis, psoriasis, arthritis psoriatica, spondylitis ankylopoetica, as well as with Crohn-disease. The adalimumab has got a high affinity binding to tumor necrosis factor (TNF) -alfa, this way it inhibits the interactions with TNF and its receptors (soluble and membrane associated). It could be well tolerated and safe, it improves the the quality of life in patients. The possible side effects can be decreased by the careful observation and usual control of patients. The authors discuss in details the publications connected with adalimumab in the above mentioned diseases.

KW - Adalimumab

KW - Crohn disease

KW - Psoriasis

KW - Rheumatoid arthritis

KW - Spondylitis ankylopoetica

KW - Tumor necrosis factor inhibition

UR - http://www.scopus.com/inward/record.url?scp=68149152801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149152801&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28681

DO - 10.1556/OH.2009.28681

M3 - Article

VL - 150

SP - 1215

EP - 1222

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 26

ER -